Introduction
Porphyrias are inherited or acquired metabolic disorders in which the clinical manifestations are attributable to characteristic patterns of overproduction of specific heme precursors and their accumulation in certain tissues as a consequence of decreased activity of a specific enzyme(s) in the heme synthesis pathway, usually in association with stimulation of the initial stage of the heme-forming system by endogenous or exogenous stressors. When clinically active, and in some cases even when latent or in clinical remission, porphyrias induce high levels of heme precursors in blood, urine, and/or stool.
Porphyrias are relatively uncommon conditions but are probably underrecognized. The prevalence of genetic predisposition to porphyria probably has been underestimated in the general population because of the limited availability of clinical tests for specific heme-synthesis enzymes and because prevalence studies generally have focused more on family members of affected individuals and less on the general population. The symptomatic manifestations of porphyria, particularly the noncutaneous manifestations, are often nonspecific and may not be accompanied by supporting physical signs. Most clinicians encounter and recognize few if any cases of porphyria in the course of their careers, and in general their levels of suspicion for these conditions are low; yet diagnosis of porphyria is critically dependent on the clinician first suspecting it as a possible cause of a patient's symptoms and then ordering the specific essential diagnostic tests.
Some of the inherited porphyrias occur commonly as toxicogenetic conditions, where the genetically acquired trait is clinically latent until clinical manifestations of porphyria are triggered idiosyncratically by exposure to certain therapeutic drugs, chemicals, or alcohol. Porphyria also can occur as an acquired toxin-induced condition, where biochemical and clinical manifestations of the porphyria are actually caused by exposure to certain chemicals in individuals with no evident genetic predisposition. In addition, certain chemicals can produce disturbances of heme synthesis that are associated with alterations of subcellular structure and functions and characteristic changes in patterns of hemeprecursor excretion. These measurable changes offer potential biological markers for detecting harmful effects of specific chemical exposures while their biological effects are still preclinical and potentially reversible. Most clinicians, however, including specialists in occupational and environmental medicine, are relatively uninformed about these phenomena.
It has recently been proposed that a variety of chemical-associated illnesses for which there are no widely accepted specific diagnostic tests or etiologic explanationssuch as multiple chemical sensitivity (MCS) syndrome, Persian Gulf War illnesses, conditions associated with silicone breast implants, and various fatigue syndromes-may represent either mild chronic cases of porphyria, or, at least in part, manifestations of acquired abnormalities in heme synthesis. Although diagnoses of porphyria and porphyrialike conditions in such cases are commonly dismissed by other clinicians and researchers, these diagnoses are increasingly put forth as objective justification for recommending major lifestyle modifications and therapeutic interventions in individual cases.
This article reviews pertinent medical and scientific literature in order to provide a foundation to address current issues related to environmental chemical exposures and possible disturbances of heme synthesis. The first three sections of this review provide necessary background information about heme synthesis and the classification and biochemistry of porphyria; more detailed information is available in the cited general references (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) .
Heme Synthesis
Heme is a biological compound that, when combined with certain proteins, plays a central role in a variety of vital physiologic functions, including oxygen binding and transport (hemoglobin and myoglobin), respiratory electron transport (cytochromes a, a3, bl, c, and cl), activation and decomposition of hydrogen peroxide (catalase and peroxidase), and other oxidation-reduction functions (cytochromes P450 and b5). Heme synthesis, which is often also referred to as porphyrin metabolism, occurs in all human cells. It is especially productive in the erythropoietic cells in bone marrow, where nearly all of the heme is used for hemoglobin, and in the liver, where the heme is primarily needed in cytochrome P450.
Heme, or iron-protoporphyrin IX, is produced by a metabolic pathway that involves eight enzyme-controlled steps (see below and Figure 1 ).
Succinyl CoA and glycine are combined to form 6-aminolevulinic acid sis. Enzyme name, step 1, ALA synthase; step 2, ALA dehydratase; step 3, PBG deaminase (uroporphyrinogen synthase); step 4, uroporphyrinogen-ill cosynthase; step 5, uroporphyrinogen decarboxylase; step 6, coproporphyrinogen oxidase; step 7, protoporphyrinogen oxidase; step 8, ferrochelatase. "ALA is synthesized within mitochondria in step 1 and then traverses to cytoplasm, where step 2 occurs. Coproporphyrinogen IlIl is synthesized in cytoplasm in step 5 and then traverses into mitochondria, where step 6 occurs. bintermediate precursors not shown for step 5 (7-, 6-, and 5-carboxyl porphyrinogens) or step 6 (3-carboxyl porphyrinogen). cAlternative pathway at step 4 Figure 1) . blhere is apparent interference by lead with these steps. In cases of lead intoxication, there may be mechanisms other than lead inhibition of the enzymes at steps 6 and 8 [Rossi ( 11) ].
Porphyrias with Neurologic Manifestations
Symptoms in the neurologic porphyrias [ALA dehydratase (ALA-D) deficiency porphyria (ADP) and acute intermittent porphyria (AIP)] and noncutaneous symptoms in the neurocutaneous porphyrias [hereditary coproporphyria (HCP) and variegate porphyria (VP)] tend to occur in intermittent acute attacks, with variable degrees of symptom presence between attacks. Clinical onset of the neurologic and neurocutaneous porphyrias usually occurs in postpubertal adolescents or adults; attacks are more common in women than men. Only six cases of ADP have been reported (7) . AIP is one of the more prevalent types of clinically manifested porphyria, at least in the United States.
All the neurologic and neurocutaneous porphyrias (except ADP) are classified as hepatic porphyrias because the liver is a principal site in which the enzyme deficiency manifests itself biochemically. Liver function abnormalities are common but are generally mild or moderate (12) . Several studies have indicated that individuals with AIP are at risk for developing hepatocellular carcinoma (13) (14) (15) (4, 7, (16) (17) (18) . If and when symptoms develop in a genetically predisposed individual, the initial onset and any subsequent recurrences often are linked to precipitating factors such as use of a therapeutic drug, exposure to a provocative chemical, alcohol consumption, tobacco smoking, an infection, the menstrual cycle, or fasting (1) .
The frequency and severity of symptom attacks vary widely both among and within individuals. In most cases, symptom attacks have discernible onsets, are characterized by moderate or severe pain, last several days or longer (up to weeks or months), and are followed or separated by periods of clinical remission. Attacks are usually recurrent but not necessarily (18) . Some manifestations of acute attacks can persist after the other clinical and biochemical manifestations subside or resolve; this is particularly true for peripheral motor neuropathy, which can take up to 1 year to resolve or can become permanent (19, 20) . Permanent neurological deficits are not necessarily accompanied by heme precursor abnormalities when a patient's porphyria is otherwise in remission.
In contrast to the typical acute presentation, symptoms in some cases can occur nondistinctly in time and/or be relatively mild and some symptoms, particularly pain or psychiatric manifestations, can become chronic, often with variable severity over time (7, 9, 21) . Given such complex presentations as well as the frequent paucity of physical signs, the diagnosis of porphyria can be delayed or missed entirely. Accordingly, screening surveys of psychiatric inpatients have reported a relatively high prevalence of individuals with previously unrecognized porphyria (22) (23) (24) (26, 27 (33) .
PCT is usually associated with some degree of liver abnormality (2, 3, 8 (27) . Porphyrins are always increased in the plasma of patients with active cutaneous lesions (10) .
When an individual has symptomatic manifestations of a porphyria (i.e., when dinically active and not latent or in remission), the level of the most excessively excreted heme precursor is typically at least several-fold greater than the values reported for the upper limit of normal. In reports describing the neurologic porphyrias, for example, urine ALA and PBG in AIP increased acutely to 8 to 150 and 30 to 200 mg/day, respectively (normal upper limits, 3 to 7.5 mg/day, depending on the laboratory) (7, 20, 26, (55) (56) (57) ; and in ADP, urine ALA was markedly elevated and urine and erythrocyte porphyrins were elevated up to 100 times (7, 10) . In reports ofthe neurocutaneous porphyrias, urine coproporphyrin in HCP increased acutely to 4 to 190 times normal (16, 58) . In VP, one small case series reported the lowest values of urine ALA, PBG, uroporphyrin, and coproporphyrin in acute attacks to be 9, 12, 190 , and 27 times the mean control values, respectively (26) , which was consistent with the higher average values reported in a larger series (27) . In reports of the cutaneous porphyrias, urine uroporphyrin in PCT increased to about 10 to 375 times normal in over 300 reported cases (except in one case (59) , where a single value was within normal range) (60) (61) (62) (63) (64) (65) (66) (67) (68) (69) (70) (31, 65, 71) , with the exception of a single patient in whom it was elevated by only a factor of 1.4 (31) . Finally, in reports of the less common (autosomal-recessive) cutaneous porphyrias, urine porphyrins in CEP were 20 to 60 times normal (7) and in HEP, urine uroporphyrin increased by at least 20-fold and erythrocyte porphyrins increased by 5-to 10-fold (28, 29, 72) . Plasma porphyrin concentrations are markedly increased when there are active skin lesions due to any cutaneous porphyria (10 (82) . Coproporphyrin normally is excreted in bile and in urine, and impaired biliary excretion in hepatobiliary disease leads to increased coproporphyrin excretion in urine (83) . Stimulation of hepatic heme synthesis (e.g., by certain drugs) in the absence of deficiency of any heme-synthesis enzymes can lead to increased coproporphyrin excretion. The kidney (primarily the epithelium of the proximal tubules) has been identified as a major source of porphyrins (primarily coproporphyrin) in the urine of normal and porphyric individuals as well as leadand mercury-poisoned individuals (84) (85) (86) (87) (99, 100) ; others noted the presence of abdominal colic and muscle weakness during the acute phase (102) . Follow-up studies up to 30 years later reported that a majority of the patients studied had cutaneous residua, arthritic deformities, thyromegaly (particularly in women), and neurologic manifestations including weakness, paresthesias, and sensory shading; smaller proportions of patients had myotonia or cogwheel rigidity without other extrapyramidal signs (103) (104) (105) (106) .
Administration of HCB to experimental animals causes a deficiency of hepatic Uro-D and a pattern of porphyrin accumulation closely resembling that in human PCT (89, (107) (108) (109) (110) (111) .
Dioxin
Laboratory experiments have demonstrated that tetrachlorodibenzodioxins (dioxin(s) or TCDDs) in high ingested doses are porphyrinogenic in rodents (112, 113) , but the evidence in humans is mixed. The strongest human evidence is from two workplace studies. In 1964, a study at a New Jersey chemical plant that produced the herbicides 2,4-dichlorophenoxyacetic acid (2,4-D) and 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) described two workers with PCT and another with possible PCT, and also reported that urine uroporphyrins were positive in 8 of 26 other workers (114) . Most workers studied had chloracne, prototypically caused by dioxin, which was then a frequent contaminant of 2,4,5-T production. Another study of 55 workers arriving at a hospital from a Czechoslovakian herbicide manufacturing plant found a high prevalence of chloracne, 11 workers with PCT, and slightly increased urine uroporphyrin (< 100 pg/ 24 hr; reference range not stated) in 21% of those tested (115) . One worker in a TCDD-contaminated workplace developed PCT, sarcoma, and probable chloracne; the combined occurrence of these rare conditions suggested an etiological relation to the TCDD exposure (116, 117 (122) . A later study, however, reported chloracne but no PCT attributable to TCDDs among Seveso children and adolescents (123, 124) . In two studies of Missouri communities where TCDD-contaminated waste oil had been sprayed for dust control over several years, there were no cases of PCT, but one study found significantly higher mean uroporphyrin levels in urine and higher prevalence of elevated urine uroporphyrin values (> 13 pg/g creatinine (cre) in 16%, vs 7% controls) among 154 residents of a contaminated mobile home park compared to matched control subjects (125, 126) .
Other Halogenated Hydrocarbons A number of halogenated hydrocarbons have been demonstrated experimentally to be porphyrinogenic in exposed animals or in in vitro tests; these are well summarized in Strik et al. (96) and Marks (97) and will not be described in this review. The reported human experience is less extensive. Haberman et al. (127) mentioned that a case of PCT manifested itself soon after agricultural application of DDT. Lynch et al. (128) reported a case of PCT in association with hepatitis, which was attributed to chronic toxic exposure and presumed to be a polychlorinated phenol unintentionially synthesized on a regular basis by mixing cleaning agents containing benzylchlorophenol and sodium hypochlorite. A worker with severe acute methyl chloride intoxication had marked increase in urine and fecal excretion of coproporphyrin but not uroporphyrin or protoporphyrin; the coproporphyrinuria decreased in association with clinical improvement (129) . Evaluation of 46 workers exposed to vinyl chloride in a polyvinyl chloride production process found that 36 had coproporphyrinuria (<820 nmol/24 hr; normal (nl) < 130), including 4 who also had mildly increased excretion of uroporphyrin and heptacarboxyl porphyrin in urine (130) . A study of Michigan farm families exposed to polybrominated biphenyls (PBBs) by ingestion of contaminated meat and dairy products found that 11 of 126 persons had coproporphyrinuria (93-218 pg/liter; nl <78), including 4 with mild uroporphyrinuria (29-59 pg/liter; nl <24) (131 in Yusho, Japan, about 10 years after the event, found no differences in urine porphyrins compared to those of controls and identified PCT in 1 person whose history was complicated by alcohol use (133, 134) . Total urine porphyrins were not significantly different from those of controls in 168 chemical plant workers exposed to either allylchloride, hexachlorocyclopentadiene, epichlorohydrin, or endrin (135).
Lead
Lead absorption, both acute and chronic, is well documented to affect heme synthesis (11) . Lead causes accumulation of zinc protoporphyrin (ZPP) in erythrocytes and large increases of ALA and coproporphyrin in urine. Lead reversibly inhibits ALA-D and also appears to interfere with the function of coproporphyrinogen oxidase and ferrochelatase, possibly by mechanisms other than direct enzyme inhibition (11, 98, 136, 137) . It is conceivable that the coproporphyrinuria occurs by the same mechanism as in ALA loading of normal subjects (Biochemistry of Porphyrias).
There is evidence that ALA-D polymorphism may influence lead toxicokinetics. The ALA-D enzyme is comprised of eight identical subunits coded by an autosomal gene, at which there are two common alleles (138) . The ALA-DI allele has about 80 to 90% prevalence in studied European and American population samples; the ALA-D2 allele, about 10 to 20% (138) (139) (140) (141) (142) (153) . However, the heterozygous defect appears to increase the vulnerability of the individual to the effects of exogenous agents such as lead, which reduce ALA-D activity. In case reports of individuals who had a heterozygous defect affecting ALA-D and were exposed to lead, the biochemical abnormalities and clinical features of illness were consistent with lead intoxication but were much more severe than expected for their mildly elevated blood lead levels (22-43 pg/dl) (149, 154, 155) . The prevalence of the heterozygous defect in the general population has been estimated variably to be below 1% (149) or as high as 2% (156) .
Other Metals
Mercury, arsenic, and other metal exposures are also reported to affect heme synthesis in humans, although the associated levels of porphyrinuria are lower than those seen with lead. In a survey of dentists attending an annual professional meeting, those who were found to have >20 pg/liter mercury in spot urine samples also had 2-to 3-fold higher levels of coproporphyrin in urine (42 ± 18 pg/g cre or 74 ± 8 pg/liter; mean ± SD) than those with no urinary mercury (coproporphyrin 28 ± 12 pg/g cre and 23 ± 6 pg/liter) (87) . Urine uroporphyrin excretions did not differ significantly; however, pentacarboxyl porphyrin and an atypical porphyrin tentatively identified as keto-isocoproporphyrin were significantly elevated in urine. A study of random urine samples from 52 workers exposed to inorganic and organic mercury (median urine mercury about 500 pg/liter) found that 23% had elevated coproporphyrin levels (>70 pg/liter and up to 159 pg/liter) compared to only 3% of control subjects (157) . Similarly, a study of arsenicexposed smelter workers (urine arsenic 129 ± 109 pg/g cre in the high-exposure group) found more than twice as much coproporphyrin (63±30, range 18-171, pg/g cre) but comparable amounts of uroporphyrin in morning urine specimens, relative to those of nonexposed control subjects (coproporphyrin 27 ± 14, range 2-57, pg/g cre) (158) . In another study, individuals exposed to arsenic in drinking water (urine arsenic mean 65, range 1-130 pg/liter) were reported to have no significant increase in urine porphyrin levels relative to those of a control group, although most exposed individuals did have inversion of the urine coproporphyrin/uroporphyrin ratio (76%, vs 32% of controls) (159) . Downey (160) (163) . In two reported case series ofacute porphyria, paints and solvents were described as triggers of acute symptoms in a number of genetically predisposed individuals (26, 164 (182) . Of the 21 elevated heme precursor values (most often coproporphyrin), 17 (8 1 %) were 1. 1 to 1.8 times higher than the respective value reported for the upper limit of normal, and 4 (2 in stool and 2 in urine) were 2.0 to 2.3 times higher (182) . Downey (167) mentioned that about 90% of 62 patients (including the above-described 19) were found to have one or more heme-synthesis enzyme abnormalities.
Two types of hypotheses have been put forth in explanation of such laboratory findings occurring with otherwise unexplained chemical-associated illnesses. The first hypothesis is that these illnesses are actually porphyrias, in which illness is precipitated by environmental chemical exposures in genetically predisposed individuals (160, 167, 172) . Proponents suggest that the latent genetic traits for various porphyrias are much more common in the general population but were not recognized until the recent increased availability of laboratory assays for the activity of heme-synthesis enzymes. It is hypothesized that such genetically predisposed individuals can manifest porphyria symptoms in low-grade smoldering or chronic and slowly progressive patterns (without classically recognizable acute attacks of severe symptoms) in response to exposures to a variety of substances such as "formaldehyde, other aldehydes, heavy vehicle exhaust fumes, perfumes, other fragrances, chlorine, chlorinated cleaning agents, possibly any chlorinated hydrocarbon, substances in poorly ventilated buildings, and anything that triggers porphyria symptoms" (172) . It is contended that these chronic symptom patterns are not necessarily accompanied by diagnostic abnormalities of heme precursors, possibly because a "limited attack especially on a small number of cells or on cells where the heme pathway is not a major functioning system or where the affected cells do not have ready access to external excretory processes may not raise porphyrin precursors above normal levels" (167); measurement of hemesynthesis enzyme activities, therefore, is regarded as critical to diagnosis.
The second hypothesis is that genetic predisposition may not be an essential Environmental Health Perspectives * Vol 105, Supplement I * February 1997 component of a porphyric mechanism in MCS syndrome, and that reported reductions in activity of heme-synthesis enzymes might represent an acquired deficiency attributable to exogenous toxic agents or stressors, manifesting as either an intoxication porphyria or some other as-yet undefined disorder of porphyrin metabolism (169, 171) . It is hypothesized that "the heme pathway may be just one of many sites in the body adversely affected by exposure to toxic chemicals, and that this interaction could account for many of the cutaneous, neurological and psychological symptoms reported by MCS patients, including the most controversial symptom of chemical sensitivity itself" [A Donnay, personal communication; (166) ]. Some cases of MCS syndrome are predicted to be porphyric and the others nonporphyric (171) .
Limitations of Laboratory Measures of Heme Synthesis
In evaluating the symptomatic patient with a suspected disturbance of the heme synthesis pathway, the interpretation of laboratory tests must consider the conditions of sampling and the limitations of those tests.
Methodologic Limitatons
Laboratory test results, in general, can be compromised by a variety of factors, including specimen integrity (reflecting conditions of specimen collection, processing, transport, and storage), analytical quality, limitations of analytical methods, and the applicability and specificity of reference ranges, including the range of normal intraindividual variability. Issues of specimen integrity may be particularly relevant when specimens are collected and processed at one site and then transported to a geographically distant reference laboratory, as in nearly all the cases described in "Unexplained Chemical-associated Illnesses and Measures of Heme Synthesis." Specimen integrity is a particular concern in enzyme activity assays. There is the risk of obtaining falsely low measurements of enzyme activity because of the potential lability of enzymes after removal from the body. Because It is particularly important to recognize that there can be considerable normal intraindividual variation in physiologic tests (183) ; often for specific tests either this has not been characterized or the degree of expected variability has not been made known to the clinician. Any such variation, however, can limit the clinician's ability to interpret a test result confidently as abnormal when an individual's single result is outside the reference range by an amount that is small relative to expected intraindividual variability on that test. One study, for example, reported a 3-fold difference between the highest and lowest total porphyrin measurements in 24-hr urine specimens (normally comprised mostly of coproporphyrin) collected over 7 consecutive days from the same person; all values were normal except one that exceeded the value reported for the upper limit of normal by about 25% (131) .
Finally, because a reference range may be unique to the assay method and the laboratory performing the test, test results should be interpreted relative to the laboratory-specific reference range and/or, if sufficient general clinical experience exists, against accepted absolute reference standards. However, a reference range may have limited representativeness for test subjects, even when derived from a large sample of normal individuals, if test subjects differ from the reference sample in terms of the circumstances affecting specimen integrity or in terms of potentially confounding personal factors. For example, the study of PBB-exposed Michigan farm families (see "Environmental Chemicals and Effects on Measures") found total urine porphyrins were significantly higher on average than those in the Dutch reference sample, but they were no different than those in a contemporary control group of Wisconsin farm families (131) .
Enzyme Activity Measurements
The diagnostic value of activity measurements for heme-synthesis enzymes depends on the presence or absence of symptoms and on other clinical and laboratory data, particularly the level and pattern of any associated overproduction of heme precursors. Individuals who are genetically predisposed to a porphyria usually will have deficient activity of the associated enzyme, yet a substantial proportion will never develop symptoms of a porphyria. Therefore, identification of the genetic trait alone in a symptomatic patient is not by itself sufficient evidence of symptom causality. In addition, reductions in enzyme activity do not necessarily reflect a genetic trait; certain exogenous agents such as alcohol or lead can inhibit or interfere with the activity or alter the synthesis of specific enzymes in the heme synthesis pathway (11, 74) . Conversely, normal enzyme activity measurements can reduce the likelihood, although they do not completely eliminate the possibility, that a person has porphyria. There is typically a substantial degree of overlap in enzyme activity values for normal individuals and for individuals with a porphyria characterized by deficiency in that enzyme (73, 188) . Also, some porphyrias do not necessarily manifest the associated enzyme deficiency in erythroid cells, even though it may be present in other tissues (e.g., variant AIP, when a mutation is in or near exon 1 of the PBG deaminase gene and affects only the nonerythroid enzyme) (10) .
The measurement of specific hemesynthesis enzyme activities is commonly considered a second-line test in the evaluation of porphyrias (189) . Enzyme activity measurements are most often used for identifying a genetic trait for porphyria in family members of a person with diagnosed or suspected porphyria to identify individuals who should be counseled on the need to Environmental Health Perspectives * Vol 105, Supplement * February 1997 minimize or avoid exposure to factors known to precipitate porphyria, even though they may have been asymptomatic to date (7, 188, 190, 191) . Enzyme activity measurements also can be useful when a symptomatic person is diagnosed as having a porphyria of some type-based on symptom pattern and a substantial increase in excretion of heme precursor(s)-but the pattern of heme-precursor excretion does not allow differentiation of the specific type of porphyria; proof of deficient activity for a specific heme-synthesis enzyme can facilitate determination of the specific porphyria. Measurements of enzyme activity otherwise have limited utility in the evaluation of suspected porphyria in symptomatic individuals.
CoprovorDhvrinozen Oxidase Activity
Decreased Copro-O activity is the most frequently identified enzyme finding, and in many cases is the sole basis for diagnosing a disturbance of heme synthesis in the above-mentioned cases of unexplained chemical-associated illnesses with reportedly abnormal measures of heme synthesis (see "Unexplained Chemical-associated Illnesses and Measures of Heme Synthesis").
The assay for Copro-O activity is the subject of some controversy. At present, only one laboratory offers a Copro-O activity assay on a commercial basis. That assay is performed by the incubation of ALA substrate with a lysed peripheral blood cell specimen, followed by analysis of the porphyrins formed; a low yield of protoporphyrin and a normal or increased yield of coproporphyrins indicate a deficiency of Copro-O (183) . The commercial assay, therefore, uses coproporphyrinogen synthesized enzymatically in situ from ALA added to the incubate. In contrast, research laboratories that perform Copro-O activity assays in peripheral blood cells do so in isolated leukocyte or lymphocyte fractions, using externally synthesized coproporphyrinogen as specific substrate (16, (192) (193) (194) .
It is widely believed that heme synthesis in humans is confined to nucleated cells and that Copro-O is a mitochondrial enzyme. However, there is little published information that addresses the relative degrees of Copro-O activity in reticulocytes, mature erythrocytes, and leukocytes (16, 195, 196) . Heme synthesis in peripheral blood cells is expected to occur only in leukocytes and perhaps in reticulocytes, and not in mature erythrocytes, which lack nuclei and mitochondria and which constitute about 99% of peripheral blood cells.
Mitochondria are present in nucleated blood cells but are not normally present in mature erythrocytes. Developers of the lysed-blood assay maintain, however, that circulating erythrocytes can transform 10 to 40% of available coproporphyrinogen III to protoporphyrinogen during 3-hr incubations, with reticulocytes having at least twice as much Copro-O activity as older erythrocytes, and with overall erythrocyte activity far exceeding that seen in lymphocytes (RD Ellefson, personal communication). The subcellular distribution of the reported Copro-O activity in erythrocytes is undear; remnants of mitochondria are one speculated possibility.
It is generally agreed that because the percentage of reticulocytes varies among normal persons and can change dramatically in a number of disease states, interpretation of test values from the lysed-blood assay should at least be adjusted for the reticulocyte count (183) . It is also agreed that regardless of the technique used to assay activity, Copro-O is a particularly labile enzyme after removal from the body. Vigorous specimen processing or failure to properly maintain the specimen during transport or storage can cause enzyme damage and produce falsely low (i.e., false positive) test results (183) .
Evaluating the Symptomatic Patient in Whom Porphyria Is Suspected
The most important first step toward diagnosing or ruling out porphyria in a symptomatic patient is for the clinician to maintain a high index of suspicion for a possible diagnosis of porphyria, whether symptoms are classic for a porphyria or are vague or unexplained. The conclusive diagnosis of a porphyria should be based on a systematic approach incorporating medical history, physical examination, and biochemical data, and including genetic evaluation if necessary. Certain symptom patterns, physical findings, and elements of the exposure history may raise the degree of suspicion for porphyria; however, the lack of supporting information from these sources cannot exclude a diagnosis of porphyria. Therefore, the systematic approach to evaluating a symptomatic patient with suspected porphyria must include laboratory evaluation (see also "Biochemistry of Porphyrias").
Laboratory EvaluationDiagnosis ofPorphyria
The nature and pattern of a patient's symptoms and physical signs may provide some guidance in the selection of tests for evaluating the symptomatic patient with suspected porphyria. However, the neurologic and cutaneous manifestations of porphyrias can be nonspecific or atypical and caution is necessary to avoid being overly focused on the basis of clinical appearance in initial test selection. Reviewers make slightly different recommendations regarding the appropriate panel of first-line tests for the evaluation of suspected porphyria. The most common recommendationwhen symptoms suggest possible neurologic manifestation(s) of an acute porphyria-is for the measurement of PBG with or without ALA in urine (46, 52, 54, 189 
